Insulin Icodec: First Approval.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 717, doi. 10.1007/s40259-024-00670-5
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2024 AND VI 38 AND IP 5
Results: 8
1
2
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 639, doi. 10.1007/s40259-024-00675-0
- By:
- Publication type:
- Article
3
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 657, doi. 10.1007/s40259-024-00674-1
- By:
- Publication type:
- Article
4
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 691, doi. 10.1007/s40259-024-00673-2
- By:
- Publication type:
- Article
5
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
6
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 703, doi. 10.1007/s40259-024-00676-z
- By:
- Publication type:
- Article
7
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 611, doi. 10.1007/s40259-024-00669-y
- By:
- Publication type:
- Article
8
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.
- Published in:
- BioDrugs, 2024, v. 38, n. 5, p. 681, doi. 10.1007/s40259-024-00668-z
- By:
- Publication type:
- Article